Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction.

Full Abstract

To determine whether the administration of erythropoietin (EPO) early after the onset of ischemia could enhance the preservation of jeopardized myocardium by reperfusion, 236 patients admitted <6 hours after the onset of chest pain indicative of acute coronary syndromes confirmed to be ST-segment elevation acute myocardial infarctions who were treated with tenecteplase to induce coronary thrombolysis were studied. Patients were randomized to standard care or standard care plus the administration of a single dose of EPO 30,000 IU intravenously immediately before the onset of treatment with tenecteplase. The primary end point was enzymatically estimated infarct size. The results indicated that infarct size index was virtually identical in the 2 groups, with a mean +/- SE of 13.2 +/- 0.1 creatine kinase-MB gram equivalents in controls and 12.4 +/- 0.9 creatine kinase-MB gram equivalents in patients treated with EPO. In conclusion, although the early administration of EPO was apparently safe, it did not enhance the preservation of jeopardized ischemic myocardium.

Author information

Author/s: Binbrek, Azan S (AS); Rao, Nayan S (NS); Al Khaja, Najib (N); Assaqqaf, Jamal (J); Sobel, Burton E (BE);

Affiliation: Rashid Hospital, Dubai, United Arab Emirates.

Journal and publication information

Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal: The American journal of cardiology (Am J Cardiol), published in United States. (Language: eng)

Reference: 2009-Oct; vol 104 (issue 8) : pp 1035-40

Dates: Created 2009/10/05; Completed 2009/10/20;

PMID: 19801020, status: MEDLINE (last retrieval date: 10/20/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Injections, Intravenous
Male
Middle Aged
Myocardial Infarction - blood; drug therapy; physiopathology
Prospective Studies
Recurrence - prevention & control
Thrombolytic Therapy - methods
Tissue Plasminogen Activator - therapeutic use
Treatment Outcome

Associated Chemicals: Fibrinolytic Agents (0) ; tenecteplase (0) ; Erythropoietin (11096-26-7) ; Creatine Kinase, MB Form (EC 2.7.3.2) ; Tissue Plasminogen Activator (EC 3.4.21.68)

These are the highest related articles currently in the database: